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Running title:  Validity of SF-MPQ2 Neuropathic Subscale 
 
ABSTRACT 
 
Objectives:  The purpose of this study was to conduct classical psychometric evaluation and 
Rasch analysis on the Neuropathic Qualities subscale from the Short Form McGill Pain 
Questionnaire-2 utilizing scores from persons with complex regional pain syndrome to consider 
reliability and person separation, validity (including unidimensionality), and responsiveness in 
this population.  Methods: Secondary analysis of longitudinal data from persons with acute 
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complex regional pain syndrome was utilized for analysis of the psychometric properties and fit 
to the Rasch model of the Neuropathic Qualities subscale.  We followed an iterative process of 
Rasch analysis to evaluate and address data fitting challenges.  Results: Repeated measures from 
n=59 persons meeting the Budapest criteria were used for analysis.  Both item-total correlations 
and unidimensionality analyses supported theoretical construct validity; all convergent construct 
validity hypotheses were also supported.  Responsiveness was demonstrated comparing baseline 
and one-year data at d= 0.92, with a standardized response mean of 0.97.  Data were able to fit 
the Rasch model but all Neuropathic Qualities items had disordered thresholds requiring 
rescoring.  Additionally, local dependency and differential item function were addressed by 
‘bundling’, suggesting no further item reduction would be possible.  Conclusions:   This study 
provided preliminary support for the validity and responsiveness of the Neuropathic Qualities 
subscale in persons with complex regional pain syndrome. Rasch analysis further endorses use of 
the Neuropathic Qualities subscale as a ‘stand-alone’ measure for neuropathic features, but with 
substantial background data transformations.  Replication with larger samples is recommended to 
increase confidence in these findings.   
 
Keywords:  complex regional pain syndrome, neuropathic pain qualities, Rasch analysis, 
outcome measurement 
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INTRODUCTION  
 
Complex regional pain syndrome (CRPS) is a unique pain presentation that may develop after 
trauma or surgery, or spontaneously.(1)  While some persons may see resolution of their 
symptoms in the first year,(2) others experience persistent pain and disability.(3,4)  The Special 
Interest Group for CRPS of the International Association for the Study of Pain convened a 
working group to develop recommendations for outcome measurement for clinical studies in 
CRPS (COMPACT: Core Outcome Measurement set for complex regional PAin syndrome 
Clinical sTudies).  The mandate of this group was to select a recommended core set of outcome 
measures to use in all clinical studies involving CRPS patients with the goal of supporting 
international collaborations and future meta-analyses to advance the field of CRPS research.(5)  
One of the consensus recommendations from COMPACT was to prefer the use of assessments 
that had been tested using item-response theory,(5) which considers the measurement properties 
invariant across populations, thus facilitating comparisons(6) of pain and disability between 
persons with CRPS and other diagnostic groups (for example, painful diabetic neuropathy).  
After consensus was reached, which drew substantially from the PROMIS measures(7,8) to 
address many of the key constructs, the COMPACT team deliberated on what assessments of 
pain qualities were concordant with this theoretical lens, or had existing data available that 
would permit timely Rasch analysis to consider interval-level scoring properties. 
Rasch analysis 
Rasch analysis is an item-response framework based on probabilistic modelling: simply stated, it 
considers the odds that any two persons with similar amounts of the trait of interest (for example, 
neuropathic pain symptoms) would score the same on any given scale item.  Another 
conceptualization is Rasch modelling calculates the observed vs predicted values for each item 
on a scale across all persons in the sample, and the observed vs predicted values for each person 
across items.  These predicted values are generated from other scores or known characteristics, 
also called person factors, and from the item scales themselves.  Thus items and person are ‘fit’ 
to the Rasch model, using person ability and item difficulty.  Accordingly, if someone reports 
they are able to walk a mile without pain, it would also be predicted they would positively 
answer an item about if they can easily walk a block without pain.  The item about walking a 
mile is more ‘difficult’ than the item about walking a block, and the person who is able to walk a 
mile has more ability than someone who is only able to walk a block.  Conversely, if someone 
reports severe pain, we would also predict they would not positively answer an item about 
walking a mile without pain.  These properties or ‘locations’ of item difficulty and person 
ability/disability can be visually mapped to illustrate their relationship for the particular 
assessment being examined.  
  
Developed by Danish mathematician George Rasch,(6,9) the Rasch model: 1) uses a statistical 
strategy to convert the ordinal scale measurements of individual test items into interval level 
scaling,(9) 2) identifies systematic bias (termed differential item functioning)across different 
person-level characteristics such as gender,(10) 3) relies on large sample sizes to validate the 
item characteristics (11), and 4) assumes the item measurement characteristics are not dependent 
on the study population (person characteristics) if the model can be applied, and is adequately 
powered.(12,13)  A key theoretical element is the score of any item moves predictably from less 
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difficult to more difficult (for example from 0-10, where 0 means no pain, and 10 means worst 
possible pain).  The point between any two scores (like 0,1 or 1,2) where the probability is 50/50 
a person with a set amount ability would choose 0 vs 1 is called a threshold.(9)   The orderly or 
predictable progression of thresholds is a prerequisite for achieving model fit.   
Rasch modelling also generates estimates of item reliability, where the focus is on how well 
items are differentiated on the variable of interest (analogous to Cronbach’s alpha);(9,14)  person 
separation (a similar concept to reliability, where the standard error is used to describe the spread 
or separation of person abilities);(9) and unidimensionality (which could be considered 
analogous to content validation, or factorial validity).(15)  A scale that fits the Rasch model is 
assumed to reliably allow meaningful comparisons between individuals with different abilities or 
attributes (like education, gender, or even diagnosis) but the same amount of whatever trait the 
scale is intended to measure (for example, pain interference with walking from our previous 
example).   
 
 
The Short Form of the McGill Pain Questionnaire-2 
One tool considered by COMPACT, for inclusion in the core assessment set for the assessment 
of pain qualities, was the Neuropathic Qualities subscale (NeQ) of the second version of the 
short form McGill Pain Questionnaire (SF-MPQ2).(16)  The SF-MPQ2 subscale for neuropathic 
qualities was considered appropriate to address the important domain of pain qualities.(5)  While 
many other measures of neuropathic pain are available, our concerns were 1) many were 
developed with the intent to discriminate between nociceptive and neuropathic pain features, 
rather than to measure the severity or impact of neuropathic pain,(17–20) or 2) lacked requisite 
evidence for test-retest reliability and responsiveness.(21),(22) Further, the brevity of including a 
brief scale or subscale was desirable, to minimize participant burden related to a core set of 
measures.  To date, psychometric studies of the measurement properties of the total SF-MPQ2 
have not included substantial proportions of participants with CRPS: estimates for reliability, 
validity and responsiveness arise from populations  with painful diabetic neuropathy(16), cancer 
pain,(23) acute low back pain,(24) or a mixture of pain diagnoses.(16,25)   While the scaling 
structure of the SF-MPQ2 has been validated,(16) supporting the legitimacy of each subscale as 
a unique construct, we were unaware of any published studies looking at the NeQ subscale (see 
Table 1 for an overview of the SF-MPQ2 items and subscales) as a distinct entity for outcome 
measurement.  If data generated from the NeQ subscale of the SF-MPQ2 demonstrated fit to the 
Rasch model, this would support its validity as a stand-alone outcome measure for neuropathic 
pain. When we set out to examine the SF-MPQ2, no Rasch analyses of the measurement 
characteristics had been published.  However, a recent publication reported Rasch analysis of the 
SF-MPQ2 in participants with knee osteoarthritis(26) and suggested the NeQ subscale could also 
fit the model.  Therefore, an opportunity exists to consider the measurement properties of the 
NeQ subscale of the SF-MPQ2 using Rasch modeling in a different population, and to compare 
these findings to estimates of measurement properties using traditional psychometric methods 
from classical test theory (CTT).  This would ultimately assist pain clinicians in the selection of 
evaluation tools to inform treatment planning for persons with CRPS.  The purpose of this study 
therefore, was to conduct both classical psychometric, and Rasch analysis on the NeQ subscale 
from the SF-MPQ2 utilizing scores from participants with CRPS to consider its reliability and 
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person separation, and estimate validity (including unidimensionality), and responsiveness in this 
population.   
 
Table 1.  Overview of the items of the Short Form McGill Pain Questionnaire (version 2).   
Continuous pain Intermittent pain Neuropathic pain Affective 
descriptors 
Throbbing pain Shooting pain Hot-burning pain Tiring-exhausting 
pain Cramping pain Stabbing pain Cold-freezing pain 
Gnawing pain Sharp pain Pain caused by light 
touch 
Sickening 
Aching pain Splitting pain Itching Fearful 
Heavy pain Electric shock pain Tingling or ‘pins and 
needles’ 
Punishing-cruel 
Tender Piercing pain Numbness 
Items are scored 0-10, with 0= no pain to 10=worst possible pain. 
 
METHODS 
 
Sample and Data Collection 
This study represents a secondary analysis of data collected from participants with acute CRPS 
(n=59)  referred by community and hospital-based clinics in Auckland, New Zealand between 
February 2012 and March 2014.(2,27)   The aims of the study were 1) to track symptoms and 
signs of in persons with CRPS in the first year of the diagnosis (2), 2) to identify predictors of 
recovery(27), and 3) evaluate predictors of disability and work status in early CRPS.(28)  Partner 
sites were asked to identify eligible subjects as they presented for clinic visits.  Adult subjects 
(≥18 years) diagnosed using the IASP 1994 criteria(29,30) with acute (<12 weeks) CRPS type 1 
of any limb, with no previous history of CRPS were eligible for the study. However only those 
who met the IASP Budapest research criteria for CRPS were included in the current analysis.  
Additional inclusion criteria were English literacy, and ability to provide informed consent.  
After providing informed consent, participants were assessed on three occasions: 1) at referral 
(4-116 days after symptom onset), 2) at 6 months after symptom onset, and 3) at 12 months after 
symptom onset.  See Figure 1 for a flow diagram of study recruitment.  The original study was 
approved by the New Zealand Ministry of Health Northern Y ethics committee.  Data available 
for analysis consisted of participant demographics, clinical characteristics, the CRPS Severity 
Score (CSS),(31) and self-reported questionnaires including the SF-MPQ2,(16) and the Pain 
Disability Index (PDI).(32,33)  The source study also collected data using the short Tampa scale 
for Kinesiophobia (34), Pain Catastrophizing Scale (35) Depression Anxiety Stress Scale-21 
(36), the Bath Body Perception Disturbance Scale for CRPS (37), and work status.  See Figure 2 
for a complete listing of the variables utilized for our analysis.  
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Figure 1.  Flow diagram of overall study participation 
 
Description of outcome measures 
Short-Form McGill Pain Questionnaire, Version 2  The SF-MPQ2 contains 22 pain descriptors 
(scored 0 – 10 using the anchors ‘none’ to ‘worst possible’) on 4 subscales representing 
continuous, intermittent, neuropathic or affective features.(24)  The developers reported good 
internal consistency for each subscale (ranging from 0.73 – 0.87 across several investigations in 
large samples), and discriminant validity was supported by significant differences in change 
scores across a clinical trial in those who considered themselves improved compared to those 
who did not (p<0.002 for all scales).(24) 
CRPS Severity Score  The CSS is a 17 item condition-specific clinician rating scale for CRPS 
signs which closely aligns with the Budapest diagnostic criteria(31,38).  It addresses sensory, 
autonomic, vasomotor, motor and trophic features, (rated 1/0 as present/absent), and has 
demonstrated discriminative validity to distinguish between CRPS and other forms of chronic 
pain (30).  More recently, the scale was modified to 16 items to give equal weighting to signs 
and symptoms: a multi-site prospective study reported acceptable stability (ICC=0.67) over a 3 
month period in persons with chronic (stable) CRPS, and change in CSS scores in persons with 
acute CRPS were significantly correlated with changes in pain intensity, and Rand-36 pain,  
fatigue, well-being, social functioning, and physical roles subscale scores.(39) 
Pain Disability Index The PDI is a brief 7-item self-reported evaluation of the impact of pain on 
activities and daily functioning, using 0-5 ratings for each item.(32)  It demonstrated good 
internal consistency (α=0.86) in a large cross-sectional sample, but lower test-retest reliability 
over a 2 month period (r=0.44, p<0.001).(40)  Several studies have supported discriminant 
validity for distinguishing between persons with high or low levels of disability (32,33,40) 
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Figure 2.  Variables available for analysis 
 
Data analysis 
All data sets from each time point were included in the overall analysis.  For analyses requiring 
only cross-sectional data, the longitudinal data was transformed (or ‘stacked’) by consideration 
of repeated measures from individual participants as unique data points based on duration of 
CRPS symptoms.    Cases with missing values for any items were excluded from the analysis of 
Cronbach’s alpha (reliability); however, the number of cases included in each analysis is clearly 
specified in the reporting.  For Rasch modelling, only integers are permitted as data for scaling; 
therefore a small number of responses indicating a half value were rounded up (i.e. a response of 
7.5 would be transformed to 8; this accounted for less than 2% of the study values). 
Rasch analysis was conducted using RUMM2030 software (Rumm Laboratory Pty Ltd, Perth, 
Australia) and following Tennent et al.’s iterative steps for Rasch modelling:(14,41) see Table 2 
for a brief overview of this process.  For a detailed description of a worked Rasch analysis 
intended for a clinical audience, the reader is referred to Packham & MacDermid.(41)  Using 
RUMM2030 software constrains the analysis to  9 categorical person-level factors to be used to 
describe the sample or test population relative to the construct of interest: refer to Figure 2 for 
the variables used here.  These person-level factors are also considered to develop the ‘location’, 
a Rasch rating of the item severity, which can be understood as how much of the construct of 
interest is required for a respondent to endorse any level of an individual item.  For analysis of 
reliability, validity and responsiveness, data were imported into STATA13 (StataCorp, College 
Station, TX) for statistical calculations, including: 
x Cronbach’s alpha  for the total scale and for the NeQ  subscale  
x Validity exploration testing the hypotheses that a) self-reported SF-MPQ2 total and SF-
MPQ2 NeQ scores will be substantially correlated to pain scores measured by a numeric 
rating scale and to PDI scores, and b) SF-MPQ2 NeQ scores will be moderately 
correlated to clinician-generated CSS scores.  Strength of the correlations were 
interpreted employing Landis & Koch’s recommendations where r=0 -.20 is considered 
slight, r= .21 – 40 is fair, r= .41-.60 is moderate, r= .61 - .80 is substantial, and r> .80 is 
considered excellent.(42)  
x Responsiveness of the SF-MPQ2 was estimated using the effect size and standardized 
response means, and compared to the effect sizes and standardized response means of the 
pain Numeric Rating Scale (NRS), PDI and CSS over the same interval.    
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Table 2.  Overview of the statistical analyses included in Rasch modelling (adapted from 
Packham & MacDermid) (34)  
RASCH ANALYSIS 
COMPONENT 
METHOD OF 
ANALYSIS 
HYPOTHESIS/ 
EVALUATIVE CRITERIA 
Partial credit vs. 
rating scale 
parameters 
Log-likelihood ratio If rating scale parameters are confirmed by a 
non-significant ratio test, then items do not 
vary from the core rating scale structure, and a 
rating scale format may be utilized.  If the test 
is significant, a partial credit model is used  
Response distribution Frequency plot of actual 
responses across all possible 
items and response options 
Each possible category of item/response 
should be used (this visually maps floor or 
ceiling effects); ideal to have at least 5 cases 
for each rating level of every item to ensure 
adequate analysis power 
Thresholds Graphic representation and 
plots of probability 
Ordered progression of thresholds (the point 
where there is a 50/50 probability of choosing 
either response option) from less to more of 
the latent trait of interest  
Item fit Chi-square, fit residual 
transformed to a 
standardized (Z) score 
Mean 0, SD up to 1 if data fit the Rasch 
model; reflects the divergence between 
expected and actual values looking across all 
items scored by an individual person 
Person fit Chi-square, fit residual 
transformed to a 
Z-score 
Mean, SD up to 1 if data fit the Rasch model; 
reflects the divergence between expected and 
actual values looking across all persons for a 
given item 
Item trait interaction Chi-square probability p>0.05 tests whether the items are working as 
expected (fitting the model) across the class 
intervals for the trait 
Individual person fit Chi-square analysis Values should fall within ±2.5 if the data fit 
the Rasch model 
Person separation 
index 
Cronbach’s alpha Values over 0.70 allow for group comparison, 
over 0.85 for individual comparisons of 
summed scores 
Local dependency Correlation analysis of item 
residuals  
Correlations of less than 0.3 suggest no firm 
evidence of local dependency 
Differential item 
functioning 
Item characteristic curves & 
ANOVA of item residuals 
IC curves plotted by person characteristics 
(such as gender or age) and p>0.05 for 
between groups ANOVA reveal no evidence 
of DIF 
Unidimensionality Principal component factor 
analysis is used to identify 
positive and negatively 
loading items; these 
repeatedly t-tested against 
each other to ensure they are 
not significantly different; 
the proportion of significant 
t-tests is reported 
The proportion of significant t-tests will be 
less than 0.05 (or less than 5%) and/or if the 
95% confidence interval includes 0.05, 
unidimensionality is supported 
Key: SD = standard deviation; ANOVA = analysis of variance; IC = item characteristic; DIF = 
9 
 
 
 
differential item functioning 
 
RESULTS 
 
Demographics and person characteristics 
Fifty-nine participants in the Auckland study met the IASP Budapest research criteria for 
CRPS(30) and were included in this analysis.  Table 3 describes the demographics and clinical 
characteristics of this sample who were initially evaluated an average of nine weeks after the 
development of CRPS symptoms.(27)    
Table 3.  Demographics for sample N=59 
Characteristic Mean SD Range 
Age 48.2 years 13.3 18 - 72 
Duration of symptoms at baseline 
evaluation 
67.8 days 24.3 4 - 116 
Pain at baseline (NRS/10) 5.5 2.0 1 - 10 
CSS at baseline (/17) 12.6 2.0 8 - 17 
Total SF-MPQ2 (/10) at baseline 4.1 2.1 0.27 - 10 
NeQ subscale score at baseline (n=59) 3.9   2.0 0.3 - 10 
 
NeQ subscale score at 6 months (n=57) 2.3   2.2 0 - 9.2 
NeQ subscale score at 1 year (n=56) 1.9  
 
2.2 0 – 9.7 
Total PDI at baseline 38.1 14.2 14 - 67 
 Frequency Percent 
Gender F=43 
M=16 
72.9 % 
27.1 % 
Affected limb R U/E= 33 
L U/E=21 
R L/E=3 
L L/E=1 
Multiple= 1 
55.9 % 
35.6 % 
5.1 % 
1.7 % 
1.7 % 
Etiology 
 
 
 
None/minor=5 
Soft tissue=2 
Minor surgery=21 
Fracture=20 
Fracture+surgery=11 
8.5 % 
3.4 % 
35.6 % 
33.9 % 
18.6 % 
Key: CSS= CRPS Severity Score, NeQ= Neuropathic Qualities, NRS= Numeric Rating Scale, PDI=Pain Disability 
Index, SD=standard deviation, SF-MPQ2= Short-Form of the McGill Pain Questionnaire (version 2), F=female, 
M=male, R=right L=left, U/E= upper extremity, L/E=lower extremity 
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Rasch analysis of the NeQ scale of SF-MPQ2 
The total of complete data sets available for this analysis after considering repeated measures 
data as cross-sectional were n=156.  The log likelihood ratio was calculated at p>0.05, therefore 
the partial credit model was utilized for analysis(14): this verifies there is not a common scale 
structure across all items, because the intervals between any two points on the scale may vary 
both within and across items.(43)  The distribution of responses failed to meet the suggested 
criteria of at least 5 responses per scoring level per item(14), as participants tended to use lower 
scores, reflecting their recovery over the 3 measurement periods  (see Table 4).   More than half 
(n=34) failed to meet Linacre’s conservative suggestion of at least 10 endorsements per scoring 
level.(44)  Thresholds for all 6 items on the NeQ scale were ‘disordered’ i.e. did not follow the 
expected progression for severity of neuropathic pain, and required rescoring by collapsing of 
scoring categories.  The final scales ranged from 4-6 response options (instead of original 11 
response options [0-10]).  The solutions for combining categories were also not uniform, 
therefore this would be very difficult to operationalize in practice.  
 Table 4.  Distribution of scoring and endorsements (n=157) 
Item/Score 0 1 2 3 4 5 6 7 8 9 10 
Burning 72 11 9 10 6 11 8 6 13 7 4 
Freezing 95 7 9 12 9 4 8 3 6 2 2 
Pain with touch 52 20 12 9 12 6 13 6 19 4 4 
Itching 88 9 19 11 6 2 7 5 4 2 4 
Tingling 31 18 13 11 13 17 11 9 16 9 9 
Numbness 40 11 9 19 14 12 5 11 16 8 12 
Key: Italicized numbers represent the number of endorsements (or participant selection of) the different scores 
 
Threshold analysis   Figure 3a provides a visual illustration of the disordered thresholds for the 
‘Tingling’ item.  The lines represent the probability of an individual choosing any given scoring 
level (0-10) relative to their predicted level of the construct of interest (or person [dis]ability): 
neuropathic pain.  The figure (Figure 3a) demonstrates a near complete overlap of the probability 
curves for a score of 0, 1, and 2.  In other words, because these curves are located below the 
average item score which is centred at 0 logits on the x axis, the probability of participants with a 
low level of neuropathic pain scoring 0, 1, or 2 is unpredictable.  Scores using this 0-10 structure 
on this item do not follow the anticipated pattern of increasing proportionally as participants 
have more neuropathic pain.  However, after collapsing the scoring categories (in this case by 
combining the scores of 1&2, 3-5, 6&7, 8&9, and retaining a score of 0 or 10 in the original 
form, yielding a new six level (0-5) scoring structure, the probability curves demonstrate a 
distinct and orderly progression across the person location values (Figure 3b).  
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Figure 3A:  Probability curve for ‘Tingling’ before correction of thresholds.   
Key: The lines represent the probability of an individual choosing any given scoring level (0-10 
in 1A; 0-5 in 1B) relative to their predicted level of Tingling.    
 
Figure 3B: Probability curves for ‘Tingling’ after collapsing of categories to correct thresholds 
Item and person fit  After threshold correction, item fit to the Rasch model was acceptable (mean 
set to 0 logits, SD=0.50, with fit residuals of x= -0.28 logits, SD 1.00); no misfitting items were 
identified and there was good distribution of items across the difficulty levels, supporting good 
targeting of the scale.(6,45)  Person fit statistics were also acceptable, (x=-1.17 logits, SD 1.13), 
but the negative mean score relative to the average difficulty of the items reflects the generally 
low scores on the SF-MPQ2 NeQ subscale (starting at 4.1/10 at baseline and decreasing over 
time).  This suggests the participants in the sample were better (i.e. had less neuropathic pain) 
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than the predicted scale average. Looking at individual person fit, 13 ‘extreme’ cases were 
identified: 12 had extremely low scores while one reported 10/10 pain on most items at final 
evaluation.  A simple clinical interpretation is the predicted vs. observed scores on the NeQ were 
not what would be expected given the ratings or ‘person characteristics’ on the other measures: 
therefore the person’s reported pain scores did not fit with the rest of their clinical picture.  
Taken together, these statistics can be interpreted as reflecting the recovery of participants across 
the longitudinal data collection period: this is further supported by the mean scores of the SF-
MPQ2 NeQ subscale at the 3 different measurement points recorded in Table 4.   
 
Local dependency and differential item function 
Local dependency was found between one item pairing, ‘Burning’ and ‘Numbness’.  This occurs 
when there is a high correlation between two items representing distinct concepts, violating the 
assumption items on a scale are independent of each other.(9)  Uniform differential item function 
was indicated between the ‘Pain with touch’ item and the CSS, suggesting participants scored 
the ‘Pain with touch’ item differently at different levels of CRPS severity [F(156,5)=5.07, 
p=0.0002].  Table 5 shows the average score on the ‘Pain with touch’ across the CSS scores. 
To address both differential item functioning and local dependency, we employed a strategy 
common to Rasch analysis and bundled the items to create subtests(14) within the NeQ subscale: 
thereby creating Subtest A = Burning, Pain with light touch and Numbness [to address the local 
dependency detailed above], and retaining the remaining items Cold/freezing, Tingling, and 
Itching independently.  This strategy resolved both the differential item function and local 
dependency, while maintaining fit to the model (see Table 6).  It is important to note that no DIF 
was found for duration of CRPS symptoms, which suggests the rating scales operated similarly 
across time points.  [Insert Tables 5 & 6 about here] 
 
Person separation index and Cronbach’s alpha 
After correction for the differential item functioning (DIF) and local dependency, the person 
separation index for the proposed model was 0.78, with the inclusion of all cases.  This suggests 
the scale is able to discriminate between at least 2 groups, but falls below the suggested level of 
0.85 for individual level precision.(14)  After rescoring of thresholds, internal consistency 
(Cronbach’s alpha) based on the rescored items is 0.81 for the 6 items of the NeQ subscale of the 
SF-MPQ2, but drops to 0.70 when the scale is partitioned to address DIF and local dependency. 
 
Unidimensionality  
After principal components factor analysis to identify negatively and positively loading items, t-
testing estimated these items sets as different in only a very small proportion of the comparisons 
p= 0.032 [95%CI 0.002 -0.066], which clearly meets the standard of p<0.05 to support 
unidimensionality.(46) 
 
Psychometric estimates from classical test theory 
13 
 
 
 
Internal consistency   Cronbach’s alpha  for the total SF-MPQ2 scale was estimated at α= 0.96, 
and α= 0.83 for the NeQ subscale.  The item-total correlation estimate above 0.95 for the entire 
scale suggests redundancy exists for this population(47) while the estimate for the NeQ subscale 
would be considered good.(48)   
Construct validity   Regression analyses to explore a priori validity hypotheses confirmed all of 
the hypotheses in both strength and direction of the relationships, supporting convergent 
construct validity.  The results of the regression analyses are summarized in Table 7. 
Responsiveness   The NeQ subscale of the SF-MPQ2 appeared to adequately assess change over 
the interval of baseline to one-year post development of symptoms.  Effect sizes and 
standardized response means for the NeQ subscale, as well as the pain NRS, PDI and CSS as 
measured over the same interval, are presented in Table 8.  [insert Table 8 about here] 
 
DISCUSSION 
 
The Rasch analysis presented here supports use of the NeQ scale for persons with CRPS, albeit 
with several limitations.  This study describes the application of the Rasch model to the NeQ 
scale of the SF-MPQ2, from a dataset collected longitudinally on 59 participants across their first 
year of CRPS symptoms.  The sample demographics were very characteristic of CRPS, with 
more women than men, more involvement of the upper extremity than lower, and fractures 
reported as the most common precipitating event.(49)  The participants were each seen 3 times 
for measurement, and the data were transformed , allowing for the cross-sectional analysis of 
n=157 complete datasets.  Rasch analysis relies on large samples to support the probabilistic 
modelling required.(9)  Given that 11 of the 66 possible scoring categories were under-utilized in 
this sample, we must assume the entire analysis was underpowered because of an uneven 
distribution of scores.  This variability in score distribution can in part be attributed to the 
recovery of the study participants across the study period.  Our finding of disordered thresholds 
for all six items is also a likely reflection of an underpowered analysis.(44,50)  Turner et al. (26) 
conducted a Rasch analysis of the SF-MP2 and NeQ scale (n=240 participants with knee OA 
completed these questionnaires): they were unable to fit the entire SF-MPQ2 to the Rasch model, 
but reported good fit of the NeQ subscale and generated a ‘Rasch conversion’ table for the total 
NeQ score.(26)   
Because our study was a post-hoc analysis of existing data, the variables available to describe the 
person-level factors were based on constructs intended to inform other investigations.(27,28)  
Nonetheless, these constructs included a condition-specific measure of symptom severity (the 
CSS), a global rating of pain (NRS), and pain-related disability (PDI).  Additional variables used 
to build the Rasch model were age, gender, and duration of symptoms.  This generated a model 
of item difficulty that was well targeted across the spectrum of sample characteristics; however, 
the average level of neuropathic characteristics experienced by participants was lower than the 
average item difficulty on the NeQ subscale.  This is concordant with the recovery expected 
across the three measurement points given the typical prognosis associated with early diagnosis 
of CRPS.(3,51,52)   
One of the rationales for conduct of a Rasch analysis is the opportunity to consider the influence 
of systematic bias in how items are scored: in Rasch terms, differential item functioning (DIF).  
Our analysis identified the potential for DIF in the ‘Pain with light touch’ item, but this influence 
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was mediated by simply considering the item alongside other items as a subtest.  Allodynia, 
which includes pain with touch,(30) is a common feature in CRPS, and has been associated with 
poor prognosis in other investigations.(4)  It is not discordant to see an almost exponential 
increase in the ‘Pain with touch’ score concomitant with an increasing CSS, particularly as 
allodynia is incorporated in the CSS as both a sign and symptom.  However, it is also important 
to note the average score still remained relatively low (the highest mean score was still less than 
3/10); again, this likely reflects the clinical recovery seen across the study interval.   
Similarly, correlations (local dependency) were seen between the ‘Burning’ and ‘Numbness’ 
items: this was again addressed by combining the items in a subtest.  In short, both the 
differential item function and local dependency suggest we could use the 6 Neuropathic Qualities 
items of the SF-MPQ2 as a unique scale for the construct of neuropathic pain, but should not use 
items individually, and may not be able to reduce the number of items on this subscale without 
alteration of the measurement properties of the remaining items (as well as the whole scale).  
This is because the estimates of the measurement properties for these individual items were 
influenced by their local dependency in this evaluation, and therefore should not be assumed to 
be invariant unless both items are used together.(9)  This is in contrast to the previous Rasch 
analysis which identified a relationship between the ‘Cold/Freezing’ and ‘Numbness’ items.(26)  
Furthermore, the person separation index findings suggest a Rasch-corrected NeQ scale based on 
our study results may be useful for discriminating between 2 groups in a clinical trial, but may 
not be reliable enough to guide individual treatment decisions.(15)  The interval level scores 
generated by Rasch transformation of the raw data (through the collapsing of scoring categories) 
also required re-calculation of all six items: while this is easily achieved by a computer or web-
based application, it would demand considerable efforts from clinicians or researchers for data 
gathered using the traditional pen-and-paper methods.   
From a classical test theory perspective, we were able to generate support for the internal 
consistency, construct validity and responsiveness of the NeQ  subscale of the SF-MPQ2.  The 
internal consistency findings were concordant with the Rasch item reliability (α= 0.83 compared 
to α= 0.81, respectively).  While all of the self-reported measures included in this analysis 
demonstrated responsiveness to the substantial changes experienced by most people in this 
sample, it is interesting to note the largest effect size was seen for the CSS (see Table 8).  This 
finding adds to the previously reported psychometric properties of the CSS,(31,39) positioning it 
as an outcome measure and not just a screening tool. 
 
Limitations 
The number of data sets included in this study (n=156) is above the recommended n=150 for 
item calibration(50) but falls below a ‘rule of thumb’ estimate of at least 250 data sets.(53)  The 
lack of endorsements for all possible responses in our results (Table 4) would suggest 
underpowering.(14)  There may also be bias introduced by our use of multiple data sets from the 
same participants (albeit from different time points).  While there are advanced analysis 
strategies to check the influence of time-point dependencies in the data, we elected not to apply 
these to an underpowered analysis.  However, the lack of DIF attributable to CRPS duration (our 
time-dependent person factor) suggested the potential time dependencies were not a strong 
influence on item measurement properties.  Other limitation include that our data were gathered 
from a single health district in a single country, and the results may not be fully generalizable.  
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Using a heterogeneous sample of participants with various forms of neuropathic pain in future 
would also support examination of potential differential item functioning on the basis of 
diagnosis: something we were unable to accomplish in our sample where all participants 
included in the analysis met the IASP Budapest criteria for the diagnosis of CRPS. Finally, as 
this was a secondary analysis of existing data, we were unable to strategically select 
theoretically-informed person factors for defining item severity and functioning in this 
population; instead, we were limited to selecting from existing variables. 
One final point of consideration is that while we examined construct validity of the NeQ 
subscale, we did not directly address content validity in this study.  We did not directly ask the 
question if the NeQ accurately represents the pain qualities experienced by persons with CRPS.  
The substantial correlation (r=0.63) seen between NeQ and CSS scores could be considered 
preliminary evidence for this form of validity; however we would advocate for the need for 
continued investigations to build evidence for content validity, including face validity, relevance 
and comprehensiveness.(54) Further, our sample may not have been the ideal study population, 
as the improving scores and low score averages reflected a recovery trajectory that may not be 
seen in other settings. 
In conclusion, on the basis of this Rasch analysis, pain clinicians can consider using the NeQ 
subscale of the SF-MPQ2 as a ‘stand-alone’ outcome measure for the neuropathic features of 
CRPS  if substantial data transformations are made in the background.  Replicating this analysis 
using a larger sample would increase the confidence in these results.  From a classical test theory 
perspective, this examination generated preliminary support for the validity and responsiveness 
of the NeQ subscale in the CRPS population.  However, test-retest reliability for this population 
group is still unknown: a key consideration given the variability associated with CRPS.(22)  
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